A federal appeals court in New Orleans is set to decide on Wednesday if the rules allowing abortion drugs by mail will stay in place. This is a direct test of a policy from the Biden era that judges have already criticized. The 5th U.S. Circuit Court of Appeals will hear arguments about whether to restore strict safety rules. That was the plan. Now, the legal battle is heating up.
The dispute centers on a specific drug called mifepristone. The Food and Drug Administration removed the requirement for patients to get this drug in person. They announced these changes during the COVID-19 emergency in April 2021. The agency approved the new rules permanently in January 2023. This move allowed certified pharmacies to dispense the medication by mail. It happened before the Supreme Court overturned Roe v. Wade.
Now, Louisiana and 23 other states are fighting back. They want the old rule back. They insist the drug must be dispensed in person again. Gabriella McIntyre, legal counsel at Alliance Defending Freedom, spoke to the Washington Examiner on Tuesday. According to her, Louisiana suffers six ways from Sunday as this mail-order abortion drug scheme circumvents its laws.
The 5th Circuit already sided with Louisiana in May. The court ordered a temporary return to in-person dispensing for the whole nation. But the Supreme Court put that order on hold. Mail delivery continues while the appeal moves forward. The appeals court in May found major flaws in the FDA’s logic. The judges said the agency relied on a lack of reported complications. This was because the FDA had reduced the rules for doctors to report problems.
The panel also criticized the research the FDA used. The agency admitted the research could not prove the drug was safe for mail delivery on its own. Deeming the ruling a textbook example of arbitrary and capricious agency action, the court spoke out. This is a serious charge against a federal agency. It suggests the rules were made without proper proof. The Trump administration has declined to defend the policy on its merits. They asked courts to wait for a new safety review.
This delay pushes the decision past the midterm elections. The Washington Examiner reported that the administration wants to avoid a ruling before voters go to the polls. But the states argue that every day counts. They say the current system undermines their near-total abortion bans. The FDA says it stopped enforcing the in-person rule during the pandemic. They planned to make that change permanent long before the court rulings.
If the court rules for Louisiana, it could end mail delivery nationwide. This would happen even in states where abortion is legal. The 23 other states supporting the effort want this to happen. They believe the current rules are dangerous. They argue the FDA failed to justify the change adequately. The agency facilitated abortions that are prohibited under state law after Dobbs v. Jackson Women’s Health Organization.
Even if the appeals court rules in favor of the states, change might not be immediate. During this review, the Supreme Court has permitted mail delivery to persist. The legal process can be slow. But the pressure on the Trump administration is real. They face a choice between defending a policy they question or letting the courts decide. The outcome will determine how these drugs reach patients across the country.
This is not just a legal technicality. It is about who makes the rules. It is about whether states can enforce their own laws. The hearing on Wednesday in New Orleans is the key moment. The result will define the future of this drug for millions of Americans. Louisiana says the harm is happening right now.
